Ascenta Capital is a New York-based private equity and venture capital firm founded in 2023 by Lorence Kim and Evan Rachlin. The firm focuses on investing in innovative companies within the life sciences sector, particularly those advancing the clinical development of meaningful medicines. Ascenta Capital typically participates in Series B and Series C funding rounds, providing substantial financial support to help companies transition from scientific foundations to clinical advancements.
Notable portfolio companies include Adarx Pharmaceuticals, Iambic Therapeutics, and Odyssey Therapeutics, each having raised significant capital with Ascenta's backing. The firm's founders bring extensive strategic and operational experience to their investments, leveraging their backgrounds to offer more than just capital. Ascenta Capital emphasizes collaboration with management teams to drive growth and innovation, ensuring that their portfolio companies receive comprehensive support throughout their development stages.
Ascenta Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
